ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Rolfo Discusses the Potential Utility of Ceritinib

Christian Rolfo, MD, PhD, MHBA
Published: Thursday, Oct 02, 2014

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

The most important potential for ceritinib is related to the activity seen in naïve patients. Rolfo says there is a possibility to use this agent early on.

There are also new combinations with ceritinib evaluating the potential to overcome resistance. Unfortunately, even with new promising agents, there is always a possibility of recurrence through mutations or transformations.

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

The most important potential for ceritinib is related to the activity seen in naïve patients. Rolfo says there is a possibility to use this agent early on.

There are also new combinations with ceritinib evaluating the potential to overcome resistance. Unfortunately, even with new promising agents, there is always a possibility of recurrence through mutations or transformations.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x